Classification of NK-large granular lymphocytic leukemia by CD56 expression
Yuxi Li1,2, Rui Cui1,2,3, Ying Yu1,2
1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, People's Republic of China.
The Oncologist
|March 10, 2025
Summary
Diminished CD56 expression in NK-large granular lymphocytic leukemia (NK-LGLL) is linked to more severe symptoms and aggressive disease. This finding highlights CD56 as a crucial prognostic marker for NK-LGLL patients.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- NK-large granular lymphocytic leukemia (NK-LGLL) is a rare, heterogeneous lymphoproliferative disorder.
- CD56 is crucial for NK-cell maturation and cytotoxicity, but its role in NK-LGLL is unclear.
Purpose of the Study:
- To investigate the association between CD56 expression and clinical/biological features in NK-LGLL patients.
- To determine if CD56 can serve as a prognostic marker in NK-LGLL.
Main Methods:
- Retrospective analysis of 47 NK-LGLL patients.
- Stratification based on CD56 expression on tumor cells.
- Evaluation of clinical symptoms, laboratory findings, STAT3 mutations, CD161 levels, bone marrow fibrosis, time to treatment, and progression-free survival.
Main Results:
- Diminished CD56 expression was associated with symptomatic disease (anemia, neutropenia, splenomegaly), STAT3 mutations, elevated CD161, and bone marrow fibrosis.
- Patients with diminished CD56 showed trends towards shorter time to treatment and progression-free survival.
- Immunosuppressive therapy led to favorable outcomes, with 87.0% remission.
Conclusions:
- Diminished CD56 expression identifies a more aggressive subset of NK-LGLL.
- CD56 is a significant potential prognostic marker for NK-LGLL.
- This study enhances understanding of NK-LGLL pathogenesis and clinical heterogeneity.
